FAQ

THK5351

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
012320162018

Related topics

Related topics

3 relations

Narrower (1)

18F-THK5351

Broader (2)

AminopyridinesQuinolines

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
THK5351
Quinolines
Aminopyridines
18F-THK5351

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer’s disease with standardized uptake value peak-alignment (SUVP) normalization
Off-target binding in the reference region is a challenge for recent tau tracers 18F-AV-1451 and 18F-THK5351. The conventional… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2018
2018
[18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia.
BACKGROUND Semantic variant primary progressive aphasia (svPPA) has been associated with a variety of proteinopathies, mainly… (More)
Is this relevant?
2017
2017
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain
18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels… (More)
Is this relevant?
2017
2017
Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia
Tau accumulation is a core pathologic change in various neurodegenerative diseases including Alzheimer’s disease and… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2017
2017
Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
The aim of this study was to compare the binding properties of several tau positron emission tomography tracers—THK5117, THK5351… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2017
Review
2017
Tau PET imaging: present and future directions
Abnormal aggregation of tau in the brain is a major contributing factor in various neurodegenerative diseases. The role of tau… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2017
2017
Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease.
This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of… (More)
Is this relevant?
2016
2016
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.
UNLABELLED Imaging of neurofibrillary pathology in the brain helps in diagnosing dementia, tracking disease progression, and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351
18F-THK5351 is a novel radiotracer developed for in vivo imaging of tau pathology in the brain. For the quantitative assessment… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
2016
2016
Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351
BACKGROUND [18F]THK5351, a recently-developed positron emission tomography (PET) tracer for measuring tau neurofibrillary tangle… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?